Phaseline

Targets › MAOB

MAOB (Amine oxidase [flavin-containing] B): drug programs, companies and trials

3 programs from 3 companies in 3 trials: 2 Phase 1, 1 Phase 3; Neurology, Psychiatry; next expected readout Dec 2026.

Catalyzes the oxidative deamination of primary and some secondary amines such as neurotransmitters, and exogenous amines including the tertiary amine, neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), with concomitant reduction of oxygen to hydrogen peroxide and participates in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. Preferentially…. (UniProt, P27338)

Open in Phaseline: the race on MAOB, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Universita di VeronaSafinamide
Monoamine oxidase B inhibitor
MAOBPhase 3PARKINSON DISEASE (Disorder)Dec 2027
Guangzhou Henovcom BioscienceHNC364 Injectable Suspension
Rasagiline pro-drug; monoamine oxidase B (MAO-B) inhibitor
MAOBPhase 1Parkinson's Disease (PD)Dec 2026
Corium InnovationsSelegiline
Monoamine oxidase B inhibitor
MAOBPhase 1Major Depressive Disorder (MDD)–

Conditions

PARKINSON DISEASE (Disorder) (1) Parkinson's Disease (PD) (1) Major Depressive Disorder (MDD) (1)

Modalities

small molecule (2), other (1)

Companies

Universita di Verona (1) Guangzhou Henovcom Bioscience (1) Corium Innovations (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.